Bioinvent and casi pharmaceuticals announce cta approval for clinical studies of bi-1206 in nhl in china

Lund, se / accesswire / december 10, 2021 / bioinvent international ab ("bioinvent") (nasdaq stockholm:binv) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the center for drug evaluation (cde) of the china national medical products administration (nmpa), china's medical product regulator, has approved a clinical trial application (cta) submitted by bioinvent's licensee in china, casi pharmaceuticals (casi). the cta is for the initiation of two clinical trials of bioinvent's novel anti-fcyriib antibody, bi-1206, in patients with non-hodgkin's lymphoma (nhl) in china.
CASI Ratings Summary
CASI Quant Ranking